{"id":"rupatadine","rwe":[],"tags":[{"label":"rupatadine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"PTAFR","category":"gene"},{"label":"R06AX28","category":"atc"},{"label":"Active","category":"status"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Urticaria","category":"indication"},{"label":"Teikoku Seiyaku","category":"company"}],"phase":"marketed","safety":{"safetySignals":[{"llr":508.731,"date":"","count":285,"signal":"Urticaria","source":"DrugCentral FAERS","actionTaken":"Reported 285 times (LLR=509)"},{"llr":305.053,"date":"","count":185,"signal":"Asthma","source":"DrugCentral FAERS","actionTaken":"Reported 185 times (LLR=305)"},{"llr":229.628,"date":"","count":65,"signal":"Nasal polyps","source":"DrugCentral FAERS","actionTaken":"Reported 65 times (LLR=230)"},{"llr":222.981,"date":"","count":141,"signal":"Wheezing","source":"DrugCentral FAERS","actionTaken":"Reported 141 times (LLR=223)"},{"llr":197.214,"date":"","count":66,"signal":"Upper-airway cough syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 66 times (LLR=197)"},{"llr":191.28,"date":"","count":51,"signal":"Ear pruritus","source":"DrugCentral FAERS","actionTaken":"Reported 51 times (LLR=191)"},{"llr":185.689,"date":"","count":89,"signal":"Full blood count abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 89 times (LLR=186)"},{"llr":175.341,"date":"","count":101,"signal":"Angioedema","source":"DrugCentral FAERS","actionTaken":"Reported 101 times (LLR=175)"},{"llr":164.399,"date":"","count":44,"signal":"Pulmonary function test abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 44 times (LLR=164)"},{"llr":157.009,"date":"","count":63,"signal":"Sneezing","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=157)"},{"llr":152.767,"date":"","count":48,"signal":"Chest X-ray abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 48 times (LLR=153)"},{"llr":137.527,"date":"","count":59,"signal":"Eye pruritus","source":"DrugCentral FAERS","actionTaken":"Reported 59 times (LLR=138)"},{"llr":135.865,"date":"","count":49,"signal":"Blood lactic acid increased","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=136)"},{"llr":134.543,"date":"","count":60,"signal":"Lacrimation increased","source":"DrugCentral FAERS","actionTaken":"Reported 60 times (LLR=135)"},{"llr":126.411,"date":"","count":47,"signal":"Rhinitis allergic","source":"DrugCentral FAERS","actionTaken":"Reported 47 times (LLR=126)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Teikoku Seiyaku","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=RUPATADINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:08:57.683012+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:09:03.589020+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=RUPATADINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:09:04.678074+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histamine H1 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:09:05.719139+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL91397/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:09:05.378021+00:00"}},"allNames":"rupax","offLabel":[],"synonyms":["rupatadine fumarate","rupatadine","alergoliber","pafinur","rinialer","rupafin","rupax"],"timeline":[{"date":"2017-09-27","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Teikoku Seiyaku)"}],"approvals":[{"date":"2017-09-27","orphan":false,"company":"Teikoku Seiyaku","regulator":"PMDA"}],"brandName":"Rupax","ecosystem":[{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Urticaria","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"brompheniramine","slug":"brompheniramine","company":""}],"globalPrevalence":68000000}],"mechanism":{"target":"Histamine H1 receptor","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"PTAFR","source":"DrugCentral","target":"Platelet-activating factor receptor","protein":"Platelet-activating factor receptor"}],"modality":"Small Molecule","drugClass":"rupatadine","explanation":"","oneSentence":"","technicalDetail":"Rupatadine acts as a selective and competitive antagonist of the histamine H1 receptor, inhibiting the binding of histamine to the receptor and thereby reducing the symptoms of allergic reactions."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2413","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=RUPATADINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=RUPATADINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:34:35.652988","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:09:07.034175+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cyproheptadine","drugSlug":"cyproheptadine","fdaApproval":"1961-10-17","genericCount":31,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"antazoline","drugSlug":"antazoline","fdaApproval":"1990-04-30","relationship":"same-class"},{"drugName":"triprolidine","drugSlug":"triprolidine","fdaApproval":"1983-05-17","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"azatadine","drugSlug":"azatadine","fdaApproval":"1977-03-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-class"},{"drugName":"terfenadine","drugSlug":"terfenadine","fdaApproval":"","relationship":"same-class"},{"drugName":"loratadine","drugSlug":"loratadine","fdaApproval":"1993-04-12","genericCount":29,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ketotifen","drugSlug":"ketotifen","fdaApproval":"1999-07-02","patentExpiry":"Mar 27, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"acrivastine","drugSlug":"acrivastine","fdaApproval":"1994-03-25","relationship":"same-class"},{"drugName":"azelastine","drugSlug":"azelastine","fdaApproval":"1996-11-01","patentExpiry":"Jun 4, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"epinastine","drugSlug":"epinastine","fdaApproval":"2003-10-16","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fexofenadine","drugSlug":"fexofenadine","fdaApproval":"1996-07-25","patentExpiry":"Aug 2, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"desloratadine","drugSlug":"desloratadine","fdaApproval":"2001-12-21","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"rupatadine","indications":{"approved":[{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Urticaria","source":"DrugCentral","snomedId":126485001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cyproheptadine","brandName":"cyproheptadine","genericName":"cyproheptadine","approvalYear":"1961","relationship":"same-class"},{"drugId":"antazoline","brandName":"antazoline","genericName":"antazoline","approvalYear":"1990","relationship":"same-class"},{"drugId":"triprolidine","brandName":"triprolidine","genericName":"triprolidine","approvalYear":"1983","relationship":"same-class"},{"drugId":"azatadine","brandName":"azatadine","genericName":"azatadine","approvalYear":"1977","relationship":"same-class"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-class"},{"drugId":"terfenadine","brandName":"terfenadine","genericName":"terfenadine","approvalYear":"","relationship":"same-class"},{"drugId":"loratadine","brandName":"loratadine","genericName":"loratadine","approvalYear":"1993","relationship":"same-class"},{"drugId":"ketotifen","brandName":"ketotifen","genericName":"ketotifen","approvalYear":"1999","relationship":"same-class"},{"drugId":"acrivastine","brandName":"acrivastine","genericName":"acrivastine","approvalYear":"1994","relationship":"same-class"},{"drugId":"azelastine","brandName":"azelastine","genericName":"azelastine","approvalYear":"1996","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07064707","phase":"PHASE2","title":"Rupatadine in Patients With Ulcerative Colitis","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-07-15","conditions":["Ulcerative Colitis"],"enrollment":60,"completionDate":"2026-10-21"},{"nctId":"NCT06736340","phase":"PHASE1","title":"Pharmacokinetics and Safety of Rupatadine in Participants With Hepatic Impairment Compared to Control Participants.","status":"COMPLETED","sponsor":"Noucor Health S.A.","startDate":"2022-11-17","conditions":["Hepatic Impairment"],"enrollment":26,"completionDate":"2025-04-09"},{"nctId":"NCT06708520","phase":"PHASE1","title":"Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants","status":"RECRUITING","sponsor":"Noucor Health S.A.","startDate":"2022-11-21","conditions":["Renal Impairment"],"enrollment":48,"completionDate":"2025-07"},{"nctId":"NCT04601324","phase":"PHASE4","title":"Allergic Rhinitis Combination Pharmacotherapy Efficacy Study","status":"WITHDRAWN","sponsor":"St. Paul's Sinus Centre","startDate":"2020-12-15","conditions":["Allergic Rhinitis"],"enrollment":0,"completionDate":"2021-07-01"},{"nctId":"NCT05356143","phase":"PHASE1","title":"A Comparative Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"J. Uriach and Company","startDate":"2021-12-02","conditions":["Healthy"],"enrollment":45,"completionDate":"2023-01-05"},{"nctId":"NCT00199238","phase":"PHASE2","title":"Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria","status":"TERMINATED","sponsor":"J. Uriach and Company","startDate":"2002-10-28","conditions":["URTICARIA"],"enrollment":248,"completionDate":"2004-09-27"},{"nctId":"NCT02358265","phase":"PHASE3","title":"Chronic Urticaria - Long Term Assessment of Effects of Rupatadine","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2014-12","conditions":["Chronic Urticaria"],"enrollment":192,"completionDate":"2018-06-15"},{"nctId":"NCT03770923","phase":"PHASE3","title":"Effect of Some Drugs on Rheumatoid Arithritis Activity","status":"RECRUITING","sponsor":"Sherief Abd-Elsalam","startDate":"2018-10-01","conditions":["Rheumatoid Arthritis"],"enrollment":75,"completionDate":"2027-10"},{"nctId":"NCT01481909","phase":"PHASE2,PHASE3","title":"Study on Mastocytosis for Rupatadine Treatment","status":"COMPLETED","sponsor":"Marcus Maurer","startDate":"2010-09","conditions":["Mastocytosis"],"enrollment":30,"completionDate":"2011-11"},{"nctId":"NCT01605487","phase":"PHASE2","title":"Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2012-06","conditions":["Cold Contact Urticaria"],"enrollment":24,"completionDate":"2014-10"},{"nctId":"NCT00162786","phase":"PHASE4","title":"Comparative Effects of Rupatadine 10 mg, Hydroxyzine 50 mg and Placebo on Actual Driving Performance","status":"TERMINATED","sponsor":"J. Uriach and Company","startDate":"2005-05","conditions":["Healthy"],"enrollment":20,"completionDate":"2005-11"},{"nctId":"NCT00199251","phase":"PHASE3","title":"Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria","status":"TERMINATED","sponsor":"J. Uriach and Company","startDate":"2004-04","conditions":["Urticaria"],"enrollment":300,"completionDate":"2005-06"},{"nctId":"NCT00199225","phase":"PHASE1","title":"Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers","status":"COMPLETED","sponsor":"J. Uriach and Company","startDate":"2005-02","conditions":["Human Experimentation (Human Volunteers)"],"enrollment":160,"completionDate":"2005-07"},{"nctId":"NCT00258141","phase":"PHASE4","title":"Study With Rupatadine in Mosquito-Bite Allergic Adult Subjects","status":"UNKNOWN","sponsor":"J. Uriach and Company","startDate":"","conditions":["Allergy"],"enrollment":30,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"013131","UNII":"2AE8M83G3E","CHEBI":"CHEBI:135673","INN_ID":"7443","UMLSCUI":"C0534301","chemblId":"CHEMBL91397","ChEMBL_ID":"CHEMBL91397","KEGG_DRUG":"D07407","DRUGBANK_ID":"DB11614","PUBCHEM_CID":"133017","SNOMEDCT_US":"1162935008","IUPHAR_LIGAND_ID":"10103","SECONDARY_CAS_RN":"182349-12-8","MESH_SUPPLEMENTAL_RECORD_UI":"C103639"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Teikoku Seiyaku","relationship":"Current Owner"}],"publicationCount":210,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"R06AX28","allCodes":["R06AX28"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Teikoku Seiyaku","companyId":"teikoku-seiyaku","modality":"Small molecule","firstApprovalDate":"2001","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2017-09-27T00:00:00.000Z","mah":"Teikoku Seiyaku","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:09:07.034175+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}